• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

LOSARTAN Drug Record

  • Summary
  • Interactions
  • Claims
  • LOSARTAN chembl:CHEMBL191 Approved

    Alternate Names:

    HGP1405
    LOSARTAN
    HGP-1405
    2-N-BUTYL-4-CHLORO-5-HYDROXYMETHYL-1-[(2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL]IMIDAZOLE
    MK-954
    (2-BUTYL-4-CHLORO-1-{[2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL]METHYL}-1H-IMIDAZOL-5-YL)METHANOL
    DUP 753
    COZAAR®
    DUP 89
    drugbank:00678
    rxcui:52175
    chembl:CHEMBL191
    pubchem.compound:3961
    chemidplus:114798-26-4

    Drug Info:

    FDA Approval 1995
    Drug Class small molecule
    Drug Indications Antihypertensive Agents
    Drug Class antihypertensive agents
    Year of Approval 1995
    Drug Categories tetrazoles
    Drug Categories biphenyl compounds
    Drug Categories agents causing angioedema
    Drug Categories agents causing hyperkalemia
    Drug Categories angiotensin 2 receptor blocker
    Drug Categories angiotensin ii receptor blockers (arbs) and calcium channel blockers
    Drug Categories angiotensin ii receptor blockers (arbs) and diuretics
    Drug Categories angiotensin ii receptor blockers (arbs), plain
    Drug Categories angiotensin ii type 2 receptor blockers
    Drug Categories antiarrhythmic agents
    Drug Categories antihypertensive agents indicated for hypertension
    Drug Categories bsep/abcb11 substrates
    Drug Categories cytochrome p-450 cyp2c19 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp2c8 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 cyp3a substrates
    Drug Categories cytochrome p-450 cyp3a4 inhibitors
    Drug Categories cytochrome p-450 cyp3a4 inhibitors (strength unknown)
    Drug Categories cytochrome p-450 enzyme inhibitors
    Drug Categories cytochrome p-450 substrates
    Drug Categories drugs causing inadvertant photosensitivity
    Drug Categories oat1/slc22a6 inhibitors
    Drug Categories p-glycoprotein inhibitors
    Drug Categories p-glycoprotein substrates
    Drug Categories photosensitizing agents
    Drug Categories potential qtc-prolonging agents
    Drug Categories qtc prolonging agents
    Drug Categories ugt1a1 substrates
    Drug Categories ugt1a3 substrates
    Drug Categories ugt2b7 substrates
    (4 More Sources)

    Publications:

    Rocha et al., 2003, Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex., Exp. Physiol.
    Dickstein et al., 1998, Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure., Expert Opin Investig Drugs
    Anand-Srivastava et al., 2003, Angiotensin-II-induced enhanced expression of Gi proteins is attenuated by losartan in A10 vascular smooth muscle cells: role of AT1 receptors., Can. J. Physiol. Pharmacol.
    Ismail MA et al., 2006, Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists., J Med Chem
    Sookoian S et al., 2005, A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension., Am J Gastroenterol
    Miller JA et al., 1999, Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II., Kidney Int
    Arsenault J et al., 2010, A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity., Pharmacogenet Genomics
    Sardo et al., Effects of AT1 receptor antagonist losartan on sICAM-1 and TNF-alpha levels in uncomplicated hypertensive patients., Angiology
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Guan et al., 2004, [The effects of losartan on pulmonary arterial collagen and AT1 in chronic hypoxic rats]., Sichuan Da Xue Xue Bao Yi Xue Ban
    Donner KM et al., 2012, STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men., Hypertens Res
    Frau F et al., 2014, Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study., Pharmacogenomics
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Göktaş MT et al., 2016, Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients., Eur Rev Med Pharmacol Sci
  • LOSARTAN   NPHS1

    Interaction Score: 6.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOSARTAN   STK39

    Interaction Score: 6.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21993215


    Sources:
    PharmGKB

  • LOSARTAN   AGTR1

    Interaction Score: 2.1

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Antagonist
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    12719755 15991937 12710529 16509571 15743363 10594793 20436376 15026875 11752352 15573751


    Sources:
    TEND DTC PharmGKB TdgClinicalTrial TTD DrugBank GuideToPharmacology

  • LOSARTAN   CAMK1D

    Interaction Score: 1.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25410890


    Sources:
    PharmGKB

  • LOSARTAN   UGT2B7

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOSARTAN   UGT1A1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • LOSARTAN   CYP3A5

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • LOSARTAN   ABCB1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27338075


    Sources:
    PharmGKB

  • LOSARTAN   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528


    Sources:
    DTC PharmGKB

  • DrugBank: DB00678

    • Version: 5.1.7

    Alternate Names:
    LOSARTAN DrugBank Drug Name
    114798-26-4 CAS Number
    Act Losartan Drug Brand

    Drug Info:
    Drug Type small molecule
    Drug Groups approved
    Drug Categories agents acting on the renin-angiotensin system

    Publications:
    Rocha et al., 2003, Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex., Exp. Physiol.
    Dickstein et al., 1998, Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure., Expert Opin Investig Drugs
    Anand-Srivastava et al., 2003, Angiotensin-II-induced enhanced expression of Gi proteins is attenuated by losartan in A10 vascular smooth muscle cells: role of AT1 receptors., Can. J. Physiol. Pharmacol.

  • TEND: LOSARTAN

    • Version: 01-August-2011

    Alternate Names:
    LOSARTAN Primary Drug Name

    Drug Info:
    Year of Approval 1995
    Drug Class antihypertensive agents

    Publications:

  • TdgClinicalTrial: LOSARTAN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antihypertensive Agents
    Drug Class small molecule
    FDA Approval 1995

    Publications:

  • DTC: LOSARTAN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL191 ChEMBL Drug ID

    Drug Info:

    Publications:
    Ismail MA et al., 2006, Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists., J Med Chem

  • PharmGKB: losartan

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Göktaş MT et al., 2016, Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients., Eur Rev Med Pharmacol Sci
    Frau F et al., 2014, Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study., Pharmacogenomics

  • GuideToPharmacology: 135650532

    • Version: 29-September-2020

    Alternate Names:
    LOSARTAN GuideToPharmacology Ligand Name

    Drug Info:

    Publications:

  • TTD: Losartan

    • Version: 2020.06.01

    Alternate Names:
    D0DD0K TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL191

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21